| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424147100 | Binds virus or component thereof | 58 |
| 20080233128 | Treatment of Viral Infections - A method of treating viral infections comprises administering to a patient a regimen that is able to temporarily reduce the number or functionality of the host cells which the virus uses for its reproduction in a controlled manner. Preferably, host cells are part of the immune system. | 09-25-2008 |
| 20090092620 | FLU VIRUS HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODIES - The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group. | 04-09-2009 |
| 20090130120 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 05-21-2009 |
| 20090304708 | Preparation for the Prevention and/or Treatment of a Tissue Change of Mesenchymal Origin - The present invention concerns a preparation for preventing and/or treating a tissue change, wherein the tissue change involves tissue of mesenchymal origin or tissue changes derived therefrom and the preparation contains an antiviral agent. | 12-10-2009 |
| 20100034829 | LIQUID ANTI-RABIES ANTIBODY FORMULATIONS - The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies. | 02-11-2010 |
| 20100061995 | Immunotherapy To Treat Or Prevent Viral Infection - The prevention and treatment of influenza is described, by using passive immunization with antibodies (e.g. polyclonal, monoclonal, etc.) to one or more conserved influenza proteins. Both antibodies and fragments thereof are contemplated, raised against conserved proteins such as nucleoproteins. | 03-11-2010 |
| 20100092481 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 04-15-2010 |
| 20100098708 | METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS - The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k | 04-22-2010 |
| 20100215662 | Anti-influenza M2e antibody - Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza. | 08-26-2010 |
| 20100266606 | ANTIBODY THERAPY FOR HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS - The present invention relates to a monoclonal antibody against hemagglutinin of highly pathogenic avian influenza virus subtype H5 or functional fragment thereof, a hybridoma producing the monoclonal antibody, and a composition comprising the monoclonal antibody or functional fragment thereof. In addition, the present invention relates to a method for preventing or treating influenza virus infection by administering the composition to a subject, and an assay kit for influenza virus comprising the monoclonal antibody or functional fragment thereof. | 10-21-2010 |
| 20100278835 | NOVEL COMPOUNDS 660 - The invention provides compounds of formula (I) | 11-04-2010 |
| 20100285022 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 11-11-2010 |
| 20100322943 | THERAPEUTIC AND DIAGNOSTIC AFFINITY PURIFIED SPECIFIC POLYCLONAL ANTIBODIES - Provided herein are compositions that include a mixture of polyclonal antibodies obtained from the plasma of a plurality of individuals, and methods of making and using the same. | 12-23-2010 |
| 20110008360 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 01-13-2011 |
| 20110159001 | CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF - This invention relates generally to human monoclonal antibodies against SARS-CoV, epitopes bound by the bodies as well as to methods for use thereof. | 06-30-2011 |
| 20110206683 | PRESERVATION MIXTURE AND USE THEREOF - The invention relates to a preservation composition, a formulation comprising a preservation mixture of glutamate, a saccharide, and a polymer. Said preservation mixture is advantageously used for the preservation of a biological compound. | 08-25-2011 |
| 20120027768 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Ban virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 02-02-2012 |
| 20120064085 | ANTI-INFLUENZA M2e ANTIBODY - Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza. | 03-15-2012 |
| 20120076794 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof - Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections. | 03-29-2012 |
| 20120100150 | Influenza Hemagglutinin-Specific Monoclonal Antibodies for Preventing and Treating Influenza Virus Infection - Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin. | 04-26-2012 |
| 20120114661 | METHODS OF IDENTIFYING INFECTIOUS DISEASE AND ASSAYS FOR IDENTIFYING INFECTIOUS DISEASE - Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease. | 05-10-2012 |
| 20120128684 | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use - Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both. | 05-24-2012 |
| 20120164153 | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS - We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo. | 06-28-2012 |
| 20120171218 | Compositions And Methods For The Therapy And Diagnosis Of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 07-05-2012 |
| 20130004505 | HUMAN MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS AND HAVING NEUTRALIZING ACTIVITY AGAINST INFLUENZA A VIRUSES - The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection. | 01-03-2013 |
| 20130034564 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 02-07-2013 |
| 20130189275 | COMPOSITIONS AND METHODS FOR INHIBITION OF OR TREATMENT OF DENGUE VIRUS INFECTION - The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. | 07-25-2013 |
| 20140004123 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS | 01-02-2014 |
| 20140079715 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses - The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 03-20-2014 |
| 20140099324 | HERV-K ANTIGENS, ANTIBODIES, AND METHODS - Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K | 04-10-2014 |
| 20140348851 | ANTIBODIES DIRECTED AGAINST INFLUENZA - Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | 11-27-2014 |
| 20150023979 | Antibodies Against E7 Protein of Human Papilloma Virus (HPV) - The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7 protein is separated from the non-phosphorylated E7 protein by a step wherein the non-phosphorylated E7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated E7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated HPV protein E7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies. | 01-22-2015 |
| 20150098948 | Compositions And Methods For The Therapy And Diagnosis Of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 04-09-2015 |
| 20150352179 | COMPOSITIONS AND METHODS INVOLVING ENDOGENOUS RETROVIRUS PROTEINS - This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability. | 12-10-2015 |
| 20160009788 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE A NOROVIRUS | 01-14-2016 |
| 20160024187 | METHODS AND COMPOSITIONS RELATED TO INTRACELLULAR NEUTRALIZATION BY IgG - Disclosed are compositions, antibodies, and methods for binding intracellular antigens. | 01-28-2016 |
| 20160083456 | COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY - The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies. | 03-24-2016 |
| 20160102136 | SINGLE-DOMAIN VHH ANTIBODIES DIRECTED TO NOROVIRUS GI.1 AND GII.4 AND THEIR USE | 04-14-2016 |
| 20160145320 | Broad-Spectrum Monoclonal Antibody Recognizing HA1 Domain of Hemagglutinin of Influenza Virus - The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention. | 05-26-2016 |
| 20160168230 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE | 06-16-2016 |
| 20160200800 | ANTIBODIES DIRECTED AGAINST INFLUENZA | 07-14-2016 |
| 424148100 | Immunodeficiency virus | 14 |
| 20090191216 | Antibody or a fragment thereof, having neutralizing activity against HIV - The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof. | 07-30-2009 |
| 20100040631 | Combination Therapy of HIV Using Fusion/Entry Inhibitors Targeting GP41 - Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors with different target sites in HIV gp41 or different mechanisms of action. Also disclosed are methods of treating HIV infection by administering such compositions. | 02-18-2010 |
| 20100124553 | Methods for Treatment of HIV and Other Infections Using A T Cell or Viral Activator and Anti-Retroviral Combination Therapy - Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients. | 05-20-2010 |
| 20100183622 | VPR FUNCTION AND ACTIVITY - Pharmaceutical compositions comprising the HIV protein vpr or nucleic acid molecule encoding vpr are disclosed. Also disclosed are methods of treating patients suffering from diseases characterized by hyperproliferating undifferentiated cells such as cancer by administering such compositions. Methods of identifying compounds which have anti-HIV activity are disclosed, in particular, methods of identifying compounds which modulate the activity of vpr and of identifying compounds which inhibit vpr binding to the HIV protein gag. | 07-22-2010 |
| 20110044994 | HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 02-24-2011 |
| 20110044995 | ANTI-HIV MONOCLONAL ANTIBODY - The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies:
| 02-24-2011 |
| 20110142847 | Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41 - The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry. | 06-16-2011 |
| 20110177090 | Glycan markers and autoantibody signatures in HIV-1 and HIV-1-associated malignancies - The present invention provides compositions and methods for the specific and sensitive detection and characterization of anti-carbohydrate antibodies against immunogenic sugar moieties on microbes and abnormal cells and anti-HIV-1 protein antibodies for the development of diagnostic, prophylactic and therapeutic strategies against diseases inflicted by cancer cells or microbial pathogens. | 07-21-2011 |
| 20110236393 | MONOCLONAL ANTIBODY PRODUCTION IN B CELLS AND USES THEROF - The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter. | 09-29-2011 |
| 20120177657 | FUSION PROTEINS COMPRISING CD4 MINIMAL MODULES AND METHODS OF USE THEREOF - Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 07-12-2012 |
| 20120183557 | HIV TAT-CD4 HYBRID MOLECULES AND METHODS OF USE THEREOF - Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides. | 07-19-2012 |
| 20130028908 | MONOCLONAL ANTIBODIES DIRECTED AGAINST HIV p17 PROTEIN - Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided. | 01-31-2013 |
| 20140205612 | HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 07-24-2014 |
| 20140234332 | NOVEL HIV-2 ISOLATE - The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus. | 08-21-2014 |
| 424149100 | Hepatitis virus | 3 |
| 20090136515 | Methods of diagnosing, preventing and treating infection with Hepatitis C virus - The present invention provides a method for diagnosing hepatitis C virus (HCV) infection, a preventive agent for and a prevention method for HCV infection, a method for treating HCV infection, and a method for screening anti-HCV drug candidates. The HCV diagnostic method of the present invention comprises the detection of HCV proteins present in leukocytes. The preventive agent for HCV infection comprises an antibody against HCV proteins as an active component. The method for treating HCV infection comprises performing leukopheresis or reduction therapy on an HCV-infected patient. Further, the method for screening anti-HCV drug candidates comprises selecting, from test substances, a substance that is able to inhibit HCV infection in monocytes or is able to reduce the amount of HCV antigens to HCV-infected monocytes. | 05-28-2009 |
| 20100003262 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B - The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for diagnosing HBV and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states in humans and other animal species, including animal models, and providing an indication of the subject for infection by HBV, or development of other diseased states. | 01-07-2010 |
| 20120009196 | MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS CORE PROTEIN - The present disclosure relates to anti-HCV core protein monoclonal antibodies, methods of making them, and their uses in the prevention, diagnosis, and/or treatment of disease including HCV infections. | 01-12-2012 |
